Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
It’s been a busy month for IPOs. Numerous biotech companies announced their intentions to publicly list their stock on an exchange in the U.S. or abroad in order to gain new funding to advance developmental programs.
Weeks after securing $52 million in a Series C financing, Magenta Therapeutics is eying the raising of $100 million in an initial public offering two years after it was launched by Third Rock Ventures and Atlas Venture with $48.5 million in Series A financing.
A day after Illinois-based Aptinyx strengthened its relationship with pharma giant Allergan, the company is now eying an $80 million initial public offering of stock on the Nasdaq Exchange.
AveXis, a Novartis company based in Illinois, is investing $55 million to build a new manufacturing facility in Durham, North Carolina.
Verrica Pharmaceuticals, headquartered in West Chester, Pennsylvania, is launching an initial public offering (IPO), hoping to raise $86 million.
With the acquisition of Dublin-based Shire by Japan-based Takeda Pharmaceutical pretty much a done-deal, Takeda appears to be getting its financial house in order before it closes.
Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right.
The third time is the charm for AstraZeneca and its hyperkalemia treatment that has been dogged by manufacturing issues. After multiple rejections, the U.S. Food and Drug Administration finally gave its approval for the treatment.
MeiraGTx has filed with the U.S. Securities and Exchange Commission (SEC) its intentions to launch an initial public offering (IPO).
Only days after Eli Lilly and Company agreed to pay $1.6 billion for ARMO BioSciences, the Indianapolis-based drug company is acquiring AurKa Pharma, an oncology company.